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Background
Bipolar Disorder is a serious mental illness that affects
approximately 3–4% of the adult population and is the
sixth leading cause of disability in the world. More than
half of those patients stop taking their medication at some
point during their illness, subjecting themselves to a high
risk of relapse and an increased risk of suicide. A medica-
tion's overall efficacy and tolerability profile is therefore
vital to helping patients comply with their treatments.
Materials and methods
This is a 6-month "In Practice Evaluation Program" that
evaluates whether patients with bipolar disorder who
were treated with Quetiapine (Seroquel™) were signifi-
cantly more likely to achieve remission of their mania
symptoms.
This open label program was conducted all over Greece by
recruiting 517 patients diagnosed with Bipolar I Disorder.
Based on clinical program design the recommended titra-
tion of daily dosage was 200–800 mg Quetiapine (day 1-
day 4) and afterwards the dosage was determined individ-
ually in order to achieve remission of their symptoms. The
program design included patients' visits during a 6-month
period. The treatment efficacy objectives were measured
by Clinical Global Impression Scale (CGI). The treatment
safety parameters were followed by detailed reporting of
adverse drug reactions.
Results
517 patients (50.6% males and 49.4% females) by 78
study sites, aged 39.3+11.3 years were recruited in the pro-
gram within 6 months period of time (July-Oct 2004). At
program initiation 88 (17%) patients were hospitalized,
102 (19.7%) were newly diagnosed and 349 (67.5%)
were switched from previous therapies due to experience
of limited efficacy (46.7%) and adverse events (68.2%)
such as EPS (47.4%), weight gain (46.5%). The mean
dose of Quetiapine reached 663 mg/day (min 100, max
1600 mg/day). After 6 months treatment with Quetiapine
90% of patients were evaluated: 14.4% expressed no
change, 15.7% low, 33.5% high and 36.1% very high
improvement according to CGI scale score (p = 0.000,
Wilcoxon rank text). The program also demonstrated that
the Quetiapine group had significantly greater response
compared to previous therapies (severity of illness 59.4%
vs. 4.1 %, p < 0.001) as defined by the Clinical Global
Improvement Score (severity of the illness).
Quetiapine was well tolerated with an incidence of som-
nolence (0.4%), sedation (0.4%), dizziness (0.2%), and
weight gain (0.2%). Compliance to Quetiapine therapy
was reported as 97% at final visit.
Discussion
The results of the program show that Quetiapine was
superior to previous therapies in reducing symptoms, as
measured by CGI scores, in patients with bipolar disorder.
The improvements were noted at every assessment during
the 6-month program. In addition, approximately 69.6%
of patients receiving Quetiapine achieved remission from
their bipolar disorder symptoms.
Quetiapine also demonstrated a good safety profile in this
patient population.
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